Teva Pharmaceutical is expecting to earn $1.1 billion when it reports on Tuesday. The generic drug maker has been down on its luck in the past few months as some investors fear that it could lose patent protection on its top selling drug earlier than expected. Teva does specialize in generic drugs however, which some say is the way of the future.
"Marketing ability trumps patent protection when we're dealing with generic drugs," Said Andy "Raw" Kibbens, co-CEO of The Markets Are Open. "I believe TEVA is well positioned."
To read Kibbens' full report, click here.
No comments:
Post a Comment